# Biotech Growth Trust targets opportunity in global medical innovation

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-targets-opportunity-in-global-medical-innovation/4121261719
- Published: 2026-09-03T15:01:00+01:00
- Author: Amilia Stone

Biotech Growth Trust invests in growth-stage biotechnology companies developing 
new treatments across some of healthcare’s most important areas. Its portfolio includes
businesses working in central nervous system disorders, oncology, cardiovascular
disease, and gene and cell therapies.

The strategy is managed by OrbiMed, a specialist global healthcare investment firm.
Its biotechnology team combines investment experience with scientific and medical
expertise, including more than 30 analysts with MD or PhD qualifications. In a sector
where clinical evidence, regulatory progress and commercial potential can determine
company value, that specialist knowledge supports a focused approach to selecting
opportunities.

The Trust invests globally, giving it access to biotechnology companies across multiple
markets. OrbiMed’s venture capital capabilities also widen the opportunity set by
providing access to emerging businesses at an earlier stage of development.

The portfolio is diversified across biotechnology businesses developing new treatments
and technologies. Previous investments have included Immunomedics, Vertex Pharmaceuticals
and Argenx. The strategy focuses on companies that have the potential to establish
strong positions in important treatment areas and, in some cases, benefit from first-
mover advantages.

[BIOTECH_GROWTH_TRUST_-_Investment_in_innovation_and_opportunity](https://www.directorstalkinterviews.com/wp-content/uploads/2026/09/BIOTECH_GROWTH_TRUST_-_Investment_in_innovation_and_opportunity.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/09/BIOTECH_GROWTH_TRUST_-_Investment_in_innovation_and_opportunity.pdf)

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
